Garenoxacin

Garenoxacin

SCHEMBL2898521

CS(=O)(=O)O.C[C@H]1NCc2cc(-c3ccc4c(=O)c(C(=O)O)cn(C5CC5)c4c3OC(F)F)ccc21.O

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

gyrAgyrBparCparE

The experimentally established mechanism targets of Garenoxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 4/20 0.39
KDM4E B2RXH2 4/20 0.39
HPGD P15428 4/20 0.39
ALDH1A1 P00352 3/20 0.39
HSD17B10 Q99714 2/20 0.39
POLB P06746 1/20 0.39
PRKD3 O94806 1/20 0.39
ALOX15 P16050 1/20 0.39
OPRM1 P35372 1/20 0.39
CLK2 P49760 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TOP2A P11388 5/20 0.38
TOP2B Q02880 5/20 0.38
GSK3B P49841 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Garenoxacin SCHEMBL29711350 1.00 KCNH2 (0.39) KCNH2KDM4EHPGDALDH1A1HSD17B10
Garenoxacin SCHEMBL2898526 1.00 KCNH2 (0.39) KCNH2KDM4EHPGDALDH1A1HSD17B10
Garenoxacin SCHEMBL1649428 0.99 KCNH2 (0.40) KCNH2KDM4EHPGDALDH1A1HSD17B10
Garenoxacin SCHEMBL2902130 0.99 KCNH2 (0.40) KCNH2KDM4EHPGDALDH1A1HSD17B10
Garenoxacin SCHEMBL2901743 0.97 KCNH2 (0.40) KCNH2KDM4EHPGDALDH1A1HSD17B10
Garenoxacin SCHEMBL4995275 0.97 KCNH2 (0.40) KCNH2KDM4EHPGDALDH1A1HSD17B10
Garenoxacin SCHEMBL2897677 0.96 KCNH2 (0.42) KCNH2KDM4EHPGDALDH1A1HSD17B10
Garenoxacin SCHEMBL2897681 0.96 KCNH2 (0.42) KCNH2KDM4EHPGDALDH1A1HSD17B10
Garenoxacin SCHEMBL2897686 0.95 KCNH2 (0.42) KCNH2KDM4EHPGDALDH1A1HSD17B10
Garenoxacin SCHEMBL13575803 0.95 KCNH2 (0.42) KCNH2KDM4EHPGDALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4287439-B1 SYSTEMS FOR MACHINE LEARNING, OPTIMISING AND MANAGING LOCAL MULTI-ASSET FLEXIBILITY OF DISTRIBUTED ENERGY STORAGE RESOURCES MOIXA ENERGY HOLDINGS LTD (GB) 2025-07-23 EP claimed
US-12288014-B1 Systems and methods for predictive modeling MASSACHUSETTS MUTUAL LIFE INSURANCE COMPANY (US) 2025-04-29 US claimed
CN-117332033-B Space-time track generation method and device, computer equipment and storage medium 中国科学院深圳先进技术研究院 2024-08-16 CN claimed
CN-114310916-B Identification method and identification system for contact force during interaction of robot and environment 哈尔滨工业大学 2024-02-06 CN claimed
EP-4287439-A2 SYSTEMS FOR MACHINE LEARNING, OPTIMISING AND MANAGING LOCAL MULTI-ASSET FLEXIBILITY OF DISTRIBUTED ENERGY STORAGE RESOURCES Moixa Energy Holdings Limited (GB) 2023-12-06 EP claimed
US-20230045455-A1 Tibore the spring loaded unit PARKS KELVIN DONNELL (US) 2023-02-09 US claimed
CN-115271397-A Calculation method and device for electric power day-ahead market clearing and storage medium 广东电网有限责任公司电力调度控制中心 2022-11-01 CN claimed
EP-1031569-B1 SALT OF A 7-ISOINDOLINEQUINOLONECARBOXYLIC ACID DERIVATIVE, MONOHYDRATE THEREOF AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT TOYAMA CHEMICAL CO LTD (JP) 2010-03-17 EP claimed
US-7175856-B2 Palatable oral suspension and method BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-13 US claimed
US-20050203301-A1 Processes for producing 7-isoindoline-quinolone carboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient TOYAMA CHEMICAL CO., LTD. (JP) 2005-09-15 US claimed
US-20030187019-A1 Palatable oral suspension and method TOYAMA CHEMICAL CO., LTD. (JP) 2003-10-02 US claimed
US-20020049328-A1 Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient TOYAMA CHEMICAL CO., LTD. (JP) 2002-04-25 US claimed
US-6337399-B1 CONDENSATION OF ISOINDOLE WITH BORATE GROUP WITH QUINOLONE CARBOXYLIC ACID TOYAMA CHEMICAL CO., LTD. (JP) 2002-01-08 US claimed
EP-1031569-A1 PROCESSES FOR PRODUCING 7-ISOINDOLINEQUINOLONECARBOXYLIC DERIVATIVES AND INTERMEDIATES THEREFOR, SALTS OF 7-ISOINDOLINEQUINOLONECARBOXYLIC ACIDS, HYDRATES THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT TOYAMA CHEMICAL CO., LTD. (JP) 2000-08-30 EP claimed
CN-122008168-A Contact sensing method, device, medium, equipment and system of continuum robot 深圳科微医疗科技有限公司 2026-05-12 CN disclosed
US-12619712-B2 Secure computer architecture using state machines THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 2026-05-05 US disclosed
US-20260091958-A1 ROTOR TURNING LIFTING YOKE LIFTRA IP APS (DK) 2026-04-02 US disclosed
US-20020049328-A1 Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient TOYAMA CHEMICAL CO., LTD. (JP) 2002-04-25 US disclosed
US-6337399-B1 CONDENSATION OF ISOINDOLE WITH BORATE GROUP WITH QUINOLONE CARBOXYLIC ACID TOYAMA CHEMICAL CO., LTD. (JP) 2002-01-08 US disclosed
EP-1031569-A1 PROCESSES FOR PRODUCING 7-ISOINDOLINEQUINOLONECARBOXYLIC DERIVATIVES AND INTERMEDIATES THEREFOR, SALTS OF 7-ISOINDOLINEQUINOLONECARBOXYLIC ACIDS, HYDRATES THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT TOYAMA CHEMICAL CO., LTD. (JP) 2000-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187019-A1 Palatable oral suspension and method TAS2R20, TAS2R60, TAS2R30 KCNH2 880/4885KDM4E 782/4885HPGD 396/4885
US-20020049328-A1 Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient BRD7, IMPDH1, DDT KCNH2 979/4885KDM4E 3440/4885HPGD 135/4885
US-20050203301-A1 Processes for producing 7-isoindoline-quinolone carboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient KCNQ2, CYP4X1, HAAO KCNH2 52/4885KDM4E 601/4885HPGD 521/4885
US-20260091958-A1 ROTOR TURNING LIFTING YOKE RAE1, WAPL, TLK1 KCNH2 1061/4885KDM4E 1437/4885HPGD 3650/4885
US-12619712-B2 Secure computer architecture using state machines ATR, SAMM50, MCM4 KCNH2 2430/4885KDM4E 514/4885HPGD 4428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.